

## OVERVIEW

- Developing novel therapeutics for infectious diseases, medical countermeasures and substance abuse
- Advancing use of Bucillamine for COVID-19 and companion long COVID diagnostic, and nerve agent exposure
- Clinical study with psilocybin for substance use disorder
- Robust patent portfolio (*16 patents and patent applications*)
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)

## PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine <i>(Oral Tablet)</i>	Infectious Diseases COVID-19	Completed Phase 3	Determining next steps and international opps
Bucillamine <i>(Oral Tablet)</i>	Infectious Diseases Long COVID	Phase 2	IND filing for clinical study
Bucillamine	Medical Countermeasures Nerve Agent	Pre-clinical	Defence R&D Canada – Research funded by Suffield Research Centre, Canadian Department of National Defence
Oral Psilocybin <i>(Oral Capsule)</i>	Substance Use Disorder Methamphetamine	Phase 1/2	After study completion, to prepare for FDA end-of-Phase 2 meeting

## STRATEGIC PARTNERS

 Bucillamine Formulation	 Bucillamine Chemical Warfare
 Psilocybin Biosynthesis	 Clinical Research Psilocybin

## EXPECTED MILESTONES

- ▶ Q1-25: Results of Bucillamine for nerve agent exposure at DRDC
- ▶ Q1-25: FDA submission of Phase 2 study for Bucillamine to treat Long COVID
- ▶ Q2-25: FDA approval of Phase 2 study for Bucillamine to treat Long COVID
- ▶ Q2-25: Interim results for Phase 1/2 study for Psilocybin in Methamphetamine Disorder at University of Wisconsin
- ▶ Q2-25: Complete reformulation of Bucillamine IV for future studies in infectious diseases and rare disorders

## TEAM

### Management

Michael Frank, Chairman & CEO  
 Carmelo Marrelli, CFO  
 Derrick Welch, Advisor

### Scientific and Clinical

Dr. Kelly McKee, Dr. Arshi Kizilbash, M.D., Dr. Osnesmo Mpanju, Regulatory Affairs

### Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

## CONTACT INFORMATION

Revive Therapeutics Ltd.  
 82 Richmond Street East  
 Toronto, ON M5C 1P1

Tel: 1-888-901-0036  
 E-mail: [info@revivether.com](mailto:info@revivether.com)  
 Website: [revivether.com](http://revivether.com)

## STOCK INFORMATION

<b>Ticker:</b>	CSE: RVV, OTCQB: RVVTF, FRANKFURT: 31R
<b>Share Price:</b>	\$0.01 ( <i>Feb 21, 2025</i> )
<b>52-week High / Low:</b>	CAD \$0.035 / \$0.005
<b>Shares Outstanding:</b>	418,564,269 common shares 35,320,334 stock options 63,317,263 warrants (\$0.05 - \$0.20)
<b>Market Cap:</b>	CAD ~ 4,100,000